<DOC>
	<DOCNO>NCT02580864</DOCNO>
	<brief_summary>Individuate possible predictive factor anti-TNFalfa-induced deep remission Crohn 's disease .</brief_summary>
	<brief_title>Bologna IBD Markers</brief_title>
	<detailed_description>This trial exploratory , open vitro study human tissue . 120 patient enrol ( Caucasian , male/female,18-65 year old ) moderate-severe active Crohns disease indication anti-TNF therapy accord normal clinical practice . Simultaneously , 30 no-IBD control GI disorder , define medical history standard clinical chemistry value , afferent out-patient clinic enrol .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Main Inclusion Criteria IBD patient : Adult patient ( Caucasian ) Moderatesevere active Crohns disease ( 220≤ CDAI ≤450 ; blood CRP ≥5 mg/L and/or fecal calprotectin ≥250mg/L ) Indication antiTNF therapy accord normal clinical practice Informed consent sign Main Exclusion Criteria IBD patient : Changes Crohns disease treatment gastrointestinal medication ( include corticosteroid ) within previous 2 week prior enrollment Pregnant breastfeeding ( index date ) female patient Main Inclusion Criteria noIBD control : NoIBD adult control ( Caucasian ) GI disorder , define medical history standard clinical chemistry value , afferent outpatient clinic Informed consent sign Main Exclusion criterion noIBD control : Medical history digestive disease Digestive , renal metabolic disease , determine medical visit sa blood chemistry analysis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>